Quick Answer
SAB Biotherapeutics, Inc. reported Total Assets of $172.81 million for fiscal year 2025.
SAB Biotherapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $172.81M | +291.0% |
| 2024 | $44.20M | -47.3% |
| 2023 | $83.94M | +64.9% |
| 2022 | $50.90M | -14.3% |
| 2022 | $59.41M | -13.3% |
| 2022 | $68.49M | -15.6% |
| 2021 | $81.14M | +43.5% |
| 2020 | $56.54M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $183.45M | +241.0% | +508.9% |
| June 30, 2025 | $30.13M | -51.3% | -21.0% |
| March 31, 2025 | $38.12M | -46.6% | -13.7% |
| December 31, 2024 | $44.20M | -47.3% | -17.8% |
| September 30, 2024 | $53.80M | +89.9% | -13.1% |
| June 30, 2024 | $61.89M | +74.6% | -13.3% |
| March 31, 2024 | $71.37M | +67.3% | -15.0% |
| December 31, 2023 | $83.94M | +64.9% | +196.2% |
- SAB Biotherapeutics, Inc. showed an increase of +291.0% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, SAB Biotherapeutics, Inc.’s total assets has grown by 205.7% (from $56.54 million to $172.81 million).
- The most recent figure is from SAB Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: